BR0113250A - Forma de unidade de dosagem sólida; cristais de um sal de citalopram farmaceuticamente aceitável e método para fabricação dos referidos cristais - Google Patents

Forma de unidade de dosagem sólida; cristais de um sal de citalopram farmaceuticamente aceitável e método para fabricação dos referidos cristais

Info

Publication number
BR0113250A
BR0113250A BR0113250-4A BR0113250A BR0113250A BR 0113250 A BR0113250 A BR 0113250A BR 0113250 A BR0113250 A BR 0113250A BR 0113250 A BR0113250 A BR 0113250A
Authority
BR
Brazil
Prior art keywords
crystals
pharmaceutically acceptable
manufacturing
dosage unit
solid dosage
Prior art date
Application number
BR0113250-4A
Other languages
English (en)
Inventor
Ken Liljegren
Ole Nielsen
Per Holm
Sven Wagner
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26068858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0113250(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of BR0113250A publication Critical patent/BR0113250A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87Benzo [c] furans; Hydrogenated benzo [c] furans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"FORMA DE UNIDADE DE DOSAGEM SOLIDA; CRISTAIS DE UM SAL DE CITALOPRAM FARMACEUTICAMENTE ACEITáVEL E MéTODO PARA FABRICAçãO DOS REFERIDOS CRISTAIS". Uma forma de unidade de dosagem sólida compreendendo citalopram, a qual é preparada por compressão direta de uma mistura de base de citalopram ou um sal farmaceuticamente aceitável do mesmo e excipientes farmaceuticamente aceitável, ou por preenchimento da referida mistura em uma cápsula de gelatina resistente. Cristais grandes de um sal de citalopram farmaceuticamente aceitável e método para fabricação dos referidos cristais grandes.
BR0113250-4A 2000-08-10 2001-07-30 Forma de unidade de dosagem sólida; cristais de um sal de citalopram farmaceuticamente aceitável e método para fabricação dos referidos cristais BR0113250A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200001202 2000-08-10
DKPA200001614 2000-10-27
PCT/DK2001/000520 WO2001080619A2 (en) 2000-08-10 2001-07-30 Pharmaceutical composition containing citalopram

Publications (1)

Publication Number Publication Date
BR0113250A true BR0113250A (pt) 2003-06-24

Family

ID=26068858

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0113250-4A BR0113250A (pt) 2000-08-10 2001-07-30 Forma de unidade de dosagem sólida; cristais de um sal de citalopram farmaceuticamente aceitável e método para fabricação dos referidos cristais

Country Status (34)

Country Link
EP (1) EP1318805A2 (pt)
JP (1) JP2003531153A (pt)
KR (1) KR20030024833A (pt)
CN (1) CN1446089A (pt)
AR (1) AR030095A1 (pt)
AT (1) AT5744U1 (pt)
AU (2) AU2001100198B4 (pt)
BE (1) BE1013559A6 (pt)
BG (1) BG107578A (pt)
BR (1) BR0113250A (pt)
CA (1) CA2353693C (pt)
CH (2) CH694241A5 (pt)
CZ (1) CZ2003397A3 (pt)
DE (2) DE10139115A1 (pt)
EA (1) EA200300247A1 (pt)
ES (1) ES2172481B2 (pt)
FI (1) FI5176U1 (pt)
FR (1) FR2812811B1 (pt)
GB (1) GB2368014B (pt)
GR (1) GR1004193B (pt)
HR (1) HRP20030054A2 (pt)
HU (1) HUP0103071A3 (pt)
IE (1) IES20010693A2 (pt)
IL (1) IL154050A0 (pt)
IS (1) IS6021A (pt)
IT (1) ITMI20011637A1 (pt)
MX (1) MXPA03000837A (pt)
NL (1) NL1018741C1 (pt)
NO (1) NO20013891L (pt)
NZ (1) NZ523785A (pt)
PL (1) PL359824A1 (pt)
SK (1) SK2842003A3 (pt)
WO (1) WO2001080619A2 (pt)
YU (1) YU9003A (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS6021A (is) * 2000-08-10 2001-10-20 H. Lundbeck A/S Lyfjasamsetningar sem innihalda sítalópram
AU2001100195B4 (en) * 2001-01-05 2001-12-20 H Lundbeck As Pharmaceutical composition containing citalopram.
GB0206708D0 (en) * 2002-03-21 2002-05-01 Cipla Ltd Pharmaceutical salts
US6812355B2 (en) 2002-10-22 2004-11-02 Sekhsaria Chemicals Limited Process for the manufacture of citalopram hydrobromide from 5-bromophthalide
PT1578738E (pt) * 2002-12-23 2008-04-11 Lundbeck & Co As H Bromidrato de escitalopram e um método para a sua preparação
WO2004103361A2 (en) * 2003-05-20 2004-12-02 Ranbaxy Laboratories Limited A pharmaceutical dosage form of citalopram
HU227491B1 (en) * 2003-11-25 2011-07-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Tablet containing citalopram hydrogen bromide
WO2006038217A1 (en) * 2004-10-05 2006-04-13 Strides Acrolab Limited An improved drug delivery system of citalopram hydrobromide and process for producing the same
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
CN100353939C (zh) * 2006-01-05 2007-12-12 昆明积大制药有限公司 含西酞普兰和环糊精的抗抑郁口服药用组合物
GB2480192A (en) * 2007-02-02 2011-11-09 Ubiquisys Ltd Determining the location of a base station
WO2017020841A1 (zh) * 2015-08-03 2017-02-09 深圳信立泰药业股份有限公司 一种含有lcz696的药物组合物及其制备方法
US20240100012A1 (en) * 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
WO2024165628A1 (en) 2023-02-07 2024-08-15 Kinast Lasse An immediate-release oral pharmaceutical form of escitalopram or racemate thereof with increased api content

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1358915A (en) * 1919-04-14 1920-11-16 Amici Domenico Aeroplane
GB1358915A (en) * 1971-09-13 1974-07-03 Merck & Co Inc Directly compressed tablet and composition therefor
GB1526331A (en) 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
GB9714841D0 (en) * 1997-07-14 1997-09-17 Smithkline Beecham Plc Treatment method
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
US6977306B2 (en) 2000-05-02 2005-12-20 Sumitomo Chemical Company, Limited Citalopram hydrobromide crystal and method for crystallization thereof
IS6021A (is) * 2000-08-10 2001-10-20 H. Lundbeck A/S Lyfjasamsetningar sem innihalda sítalópram

Also Published As

Publication number Publication date
ES2172481B2 (es) 2004-08-01
GB2368014A (en) 2002-04-24
HUP0103071A3 (en) 2002-12-28
EA200300247A1 (ru) 2003-06-26
FR2812811A1 (fr) 2002-02-15
HRP20030054A2 (en) 2005-02-28
GR20010100377A (el) 2002-09-06
MXPA03000837A (es) 2003-06-06
NL1018741C1 (nl) 2002-02-12
JP2003531153A (ja) 2003-10-21
IES20010693A2 (en) 2002-07-10
CZ2003397A3 (cs) 2003-06-18
WO2001080619A2 (en) 2001-11-01
SK2842003A3 (en) 2003-09-11
DE20113195U1 (de) 2001-11-15
BG107578A (bg) 2003-09-30
HU0103071D0 (en) 2001-10-28
EP1318805A2 (en) 2003-06-18
KR20030024833A (ko) 2003-03-26
BE1013559A6 (fr) 2002-03-05
YU9003A (sh) 2006-05-25
FI5176U1 (fi) 2001-12-27
PL359824A1 (en) 2004-09-06
AU2001100198B4 (en) 2002-06-13
CN1446089A (zh) 2003-10-01
ITMI20011637A1 (it) 2003-01-27
GB2368014B (en) 2004-06-23
IL154050A0 (en) 2003-07-31
CA2353693C (en) 2003-07-22
CH694242A5 (de) 2004-10-15
AU2001100198A4 (en) 2001-08-16
IS6021A (is) 2001-10-20
ES2172481A1 (es) 2002-09-16
HUP0103071A2 (hu) 2002-05-29
CA2353693A1 (en) 2002-01-22
WO2001080619A3 (en) 2002-02-21
DE10139115A1 (de) 2002-03-28
ITMI20011637A0 (it) 2001-07-27
NO20013891L (no) 2002-02-11
CH694241A5 (de) 2004-10-15
AU2001279591A1 (en) 2001-11-07
GR1004193B (el) 2003-03-24
NO20013891D0 (no) 2001-08-09
AR030095A1 (es) 2003-08-13
AT5744U1 (de) 2002-11-25
FR2812811B1 (fr) 2006-08-18
NZ523785A (en) 2004-09-24
GB0118579D0 (en) 2001-09-19

Similar Documents

Publication Publication Date Title
BR0113250A (pt) Forma de unidade de dosagem sólida; cristais de um sal de citalopram farmaceuticamente aceitável e método para fabricação dos referidos cristais
RU2005124363A (ru) Твердые пероральные дозируемые формы валсартана
CA2326517A1 (en) New galenic preparations of meloxicam for oral administration
CY1107512T1 (el) Νεες υποκατεστημενες με βενζιμιδαζολιο μορφες δοσολογιας και μεθοδος για τη χρηση τους
BR0115382A (pt) Formulações para liberação controlada de hidrocodona, método de produzir analgesia efetiva, processo de preparação de uma forma farmacêutica de um sólido oral de liberação controlada, liberação controlada da forma farmacêutica oral e uso da forma farmacêutica
CY1112260T1 (el) Σκευασματα υδροκωδονης ελεγχομενης απελευθερωσης
EA200301223A1 (ru) Лекарственные формы окскарбазепина
EA200400862A1 (ru) Твёрдая лекарственная форма, содержащая сердцевинную таблетку с активным фармацевтическим ингредиентом, покрытую кольцеобразной оболочкой из спрессованного порошкообразного или гранулированного материала, способ приготовления такой лекарственной формы и устройство для её приготовления
CO5011053A1 (es) Procedimiento para la produccion de una forma de dosificacion solida que contiene carvedilol e hidroclorotiazida y formas farmaceuticas obtenidas por dicho procedimiento
EA200300183A1 (ru) Новое сочетание агониста (5-th2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции
BR0111868A (pt) Composições farmacêuticas
EA199900709A1 (ru) Таблетка для глотания, включающая в себя парацетамол
RU2007132971A (ru) Способы и материалы с транс-кломифеном для лечения мужского бесплодия
IS3789A7 (is) Aðferð við framleiðslu lyfjaskammta í föstu formimeð tempraðri losun virks þáttar
SE8901003D0 (sv) Snabbloesliga preparat
IS1664B (is) Ný aðferð við að framleiða útskipt 4-fenýl-4-píperídínkarboxamíð sem hefur bæði staðbundin deyfandiog kvalastillandi áhrif
HUP0500842A2 (hu) Dronedaront tartalmazó gyógyászati készítmény parenterális adagolásra
CA2432177A1 (en) Drug for prevention and/or therapy of endometriosis
WO2000025754A3 (en) Solid oral dosage forms containing alginic acid and famotidine
RU2004112422A (ru) Роувастатин в преддеменционных состояниях
YU54503A (sh) Farmaceutski sastav koji sadrži citalopram
EA200300430A1 (ru) Новые фармацевтические композиции, содержащие эпинастин и псевдоэфедрин
EA200401617A1 (ru) Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера
YU59102A (sh) JEDINJENJA KORISNA ZA LEČENJE ILI PREVENCIJU OBOLJENJA U KOJEM UČESTVUJE ALFA-2β-ADRENOCEPTOR
PE20030546A1 (es) Una forma de unidad de dosis farmaceutica del tipo de capsulas rigidas que contiene clonixinato de lisina, un procedimiento para su preparacion y el uso de dicha unidad de dosis como analgesico y/o antiinflamatorio

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2060 DE 29/06/2010.